Idiopathic facial hirsutism Skin and Connective Tissue Diseases
Conditions
Interventions
Participants were randomised using computer-generated block randomisation with a block size of 8 and a 1:1 allocation ratio. Allocation concealment was achieved using sequentially numbered opaque seal
Sponsors
Sandeman Provincial Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Women aged 18–70 years 2. Visible terminal facial hair graded moderate or severe on a validated mFG scale 3. Willing to use broad-spectrum sunscreen
Exclusion criteria
Exclusion criteria: 1. Pregnancy or lactation 2. Endocrine disorders (e.g., polycystic ovary syndrome [PCOS], thyroid disease) 3. Use of hormonal or anti-androgen therapy within 6 months 4. History of light-triggered seizures, keloids, or active facial dermatoses 5. Fitzpatrick skin type VI 6. Prior adverse reaction to eflornithine or IPL
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of participants achieving a =1-grade reduction on the modified Ferriman–Gallwey (mFG) scale, measured using the validated photographic mFG scale at week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Mean percentage reduction in terminal hair count, measured using dermoscopic digital photography analysed by Image-J software at baseline and week 24 2. Patient satisfaction scores, measured using a validated 5-point Likert scale at week 24 3. Incidence and severity of treatment-related adverse events, measured using the Common Terminology Criteria for Adverse Events (CTCAE v5.0) at each treatment session and final follow-up (week 24) | — |
Countries
Pakistan
Contacts
Public ContactMuhammad Usman Nawaz
Outcome results
None listed